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ABSTRACT 
 
 
 
There is increasing demand for new and improved antifungal agents due to an increase in 
fungal infections and diseases in patients being resistant to previous antifungals. The focus of 
this research is on the synthesis of anthraquinone, anthrone, bianthrone and hypericin type 
derivatives and the effect they have on the growth of the yeast species Schizosaccharomyces 
pombe, Lipomyces starkeyi and Saccharomyces cerevisiae. It is hoped that a new antifungal 
agent  could be  identified to combat the  threat of these  resistant  fungi  in order  to treat 
patients who have compromised immune systems due to HIV/AIDS, cancer treatments or in 
the case of organ transplant patients due to the presence of immune suppressants. The 
research approach adopted in this study includes the synthesis of anthraquinone, anthrone 
and bianthrones as hypericin derivatives and their effect on yeast by a growth inhibition assay. 
The findings of this research are that these derivatives give interesting results in the yeast 
growth inhibition assays with a few of the compounds synthesised being fungicidal in their 
activity and many of the compounds showing low inhibitory concentrations. The main 
conclusions drawn from this research are that the anthraquinone, anthrone, bianthrone and 
hypericin type derivative compounds, especially the amine derivatives of anthraquinone, show 
promise in the area of antifungal agents. The recommendations are that more derivatives are 
synthesised and the growth inhibition assay is repeated, testing for resorufin fluorescence 
inhibition, which gives greater sensitivity. 
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CHAPTER 1. INTRODUCTION 
 
 
 
 
 
 
 
 
1.1 Literature Review 
 
 
1.1.1 Fungal Infections 
 
Out of the more than 50,000 species of fungi present in the environment only 200 species are 
associated with human diseases and of these only 20 – 25 are common causes of infection.1 
Fungal infections are all highly contagious and thrive in warm, moist conditions. There are 
many different types of fungal infection of which the most common are: 
• Athletes foot,2 or Tineapedis, causes scaling, flaking and itching in infected areas, 
 
• Thrush,3 or Candida albicans, causes itching, redness and soreness of infected areas, 
 
• Ringworm,4 or dermatophytosis, is caused by fungi feeding on keratin in the skin, hair 
or nails, 
• Intertrigo,5  or Candidalintertrigois, is raw-looking, itchy and sore developing in warm 
moist areas of the body. 
The most common yeast responsible for causing infections is Candida and it accounts for the 
majority of all fungal infections found.6  For most people a fungal infection is an inconvenient 
irritation which only causes some soreness or itching and can mostly be treated with creams 
and ointments applied topically, or with oral antifungal medication. However, for some people 
a fungal infection can prove dangerous or even fatal.7 These people have a compromised 
immune system which has been caused by a variety of different reasons: HIV/AIDS,8 transplant 
patients,9   oncology  patients,9   premature babies and patients who are suffering from long 
serious illness or injury.10,11 There have been cases, however, where people have been struck 
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down with serious fungal infections when they were previously perfectly healthy although 
these instances are scarce.12 
Sometimes these infections can lead to more serious diseases like: 
 
• Blastomycosis,13  which is where the fungus is inhaled into the lungs and can then 
spread to other areas of the body like the skin, bones and joints. It is extremely rare 
with most of the cases occurring in India, Israel, Saudi Arabia and Africa. 
• Cryptococcosis,14  is another fungal infection of the pulmonary system, but when it 
 
spreads it can cause meningoencephalitis which is a swelling of the brain.15 
 
• Mucormycosis,16  is a fungal infection of the sinuses, brain or lungs and is associated 
most commonly with diabetes.17 
• Fungal sinusitis,18 controversially blamed for causing most of the cases of chronic rhino 
sinusitis, but are mostly benign or non-invasive and brought on by allergies.19 
 
1.1.2 Antifungal Agents 
 
Antifungal medications are used to treat fungal infections and they are usually obtained by 
prescription from the doctor or over the counter. Both fungi and humans are eukaryotes which 
mean they are similar at the molecular level, but this means that discovering a drug which will 
kill  the  fungus  without  affecting  the  mammalian  host  is  much  more  difficult  to  find  or 
chemically design. Many antifungal drugs can have side effects and these can prove life 
threatening, sometimes by causing anaphylaxis, if not used properly.20 
There  are  five  different  classes  of  antifungals  all  of  which  are  designed  to  exploit  the 
 
differences between mammalian and fungal cells: 
 
• Polyene   antifungals,   which   have   multiple   conjugated   double   bonds,   usually 
macrocyclic. They are amphiphilic and bind with the sterol in the fungal cell wall. The 
shorter the conjugation, the sterol binding is increased, which would make it more 
likely to bind to cholesterol and therefore toxic to animals. For example Natamycin 
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(Figure 1) a macrocyclicpolyene which binds to ergosterol in the fungal membrane 
making it more crystalline, allowing ions and small molecules to leak out causing cell 
death.21 
• Azole antifungals, which inhibit the enzyme lanosterol 14 α-demethylase, necessary 
 
for converting lanosterol to ergosterol and depletion in ergosterol in the fungal 
membrane disrupts the structure and ultimately the cell growth. For example the 
imidazole Daktarin (Figure 1).22 
• Allylamines,  inhibit  squalene  epoxidase,  another  enzyme  required  for  ergosterol 
 
synthesis. For example Lamisil (Figure 1).23 
 
• Echinocandins, can be used for systemic fungal infections in immuno compromised 
patients, they inhibit the synthesis of glucan in the cell wall via the enzyme 1,3-β 
glucan  synthase.  They  are  absorbed  poorly  when  administered  orally,  but  have  a 
greater effect when given by localised injection. For example Anidulafungin.24 
• Alternatives, which includes mostly essential oils, for example Citronella Oil.25 
 
Due to the similarity between fungi and mammalian cells antifungal medications can have side 
effects such as liver damage, oestrogen unbalancing and allergic reactions leading to 
anaphylaxis shock.26 They can also have interactions with other drugs (cytochrome P450, 
immunosuppressant’s, chemotherapeutics, antidepressants and selective serotonin reuptake 
inhibitors (SSRIs)) causing serious problems.27 
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3 
 
Figure 1The structures of Natamycin (1), Daktarin (2) and Lamisil (3) 
 
 
 
 
One  of  the  major  downfalls  of  today’s  antifungal  agents  is  that  the  fungi  are  becoming 
resistant to them.28, 29  This is most probably due to the fact fungi are living organisms and 
therefore can evolve and develop mutations which will change the way the fungi react to 
antifungal medications.30, 31 This leaves the area of developing new antifungal agents of critical 
importance to the medical world.32, 33 
 
1.1.3 Antifungal Agents Derived From Plants 
 
It was not until fairly recently that natural products became of interest to the research of 
synthetic chemists due to the realisation that simple combinatorial libraries did not have the 
complexity needed to treat antifungal infections and so natural products became the starting 
point for many new combinatorial libraries to be developed.34  Many natural products have 
seen an emergence of research and one of those is St John’s Wort.35 
 
 
St John’s Wort (Hypericum perforatum) is a perennial herb which grows up to 1m high, with a 
pungent aromaticity and bright yellow-orange flowers (Figure 2). It has been used throughout 
history for various medicinal applications with the earliest reference being in c1525 when the 
philosopher Paracelcus recommended it for treating wounds and hallucinations.36  The plant 
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gets its name from St John the Baptist whose feast day on the 24th June coincides with when it 
is in full bloom.37 
 
 
 
 
Figure 2 Hypericum Perforatum 
 
 
 
 
The five yellow petals bear a resemblance to the halo of the saint with the red sap symbolising 
his blood. Hypericum means ‘greatest health’ in Greek and the term perforatum comes from 
the tiny oil glands present in the leaves, which give them a perforated look. The most common 
use for the herbal remedy of St. John’s Wort is as a treatment for depression; it is thought that 
it inhibits serotonin reuptake similar to more conventional SSRIs and has been suggested to be 
more effective than the common SSRI, paroxetine (Figure 3), in moderate to severe 
depression.38 St. John’s Wort has medicinally active compounds in the petals, buds, leaves and 
stem of the plant which could contribute to the pharmacological effects shown, but it is the 
naphthodianthrones  and  flavanoids  which  are  the  two  most  active.  It  is  the 
naphthodianthrones which are thought to be responsible for the anti-depressive nature of St. 
John’s Wort; two of the most studied are the quinones, hypericin (1) and pseudohypericin (2) 
(Figure 4).39 
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Figure 3 The structure of Paroxetine 
 
 
 
 
 
 
 
 
(1) Hypericin: R=CH3 
(2) Psuedohypericin: R=CH2OH 
 
 
 
 
 
 
 
 
 
Figure 4 Structures of Hypericin and Pseudohypericin 
 
 
 
 
These  quinones  are  naturally  occurring  naphthodianthrones,  which  give  a  distinctive  red, 
orange or yellow pigmentation in the plants and are found in high concentrations within the 
flower petals and buds. Pasture fed animals have been known to develop a condition known as 
hypericism, which is a heightened sun sensitivity brought on by consuming large quantities of 
St. John’s Wort and this can result in severe sunburn and even death in some cases. It is 
thought that the photoactive action of the quinones is directly responsible.39 
 
1.1.4 Hypericin 
 
Hypericin can be isolated from St. John’s Wort using an extraction method which yields 0.21% 
 
w/w of the product in its crudest form,40 or it can be synthesised using techniques outlined by 
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Faulk and Motoyoshiya.41-43  X-ray diffraction studies have shown hypericin to be non-planar 
and this is because the side chains repel each other preventing a planar conformation.44 There 
are 16 possible hypericin tautomers of which the 7,14-dioxoisomer is the most stable 
configuration,45 even when it forms salts with alkali metals in both solution and crystalline 
states46. Hypericin is poorly soluble in water,47 but if bound to human serum albumin, the 
dissociation into the monomeric form aids solubility in aqueous physiological solutions.48 
 
Hypericin has been studied extensively for its application in photodynamic therapy due to it 
being one of the most powerful photosensitisers present in nature, possibly due to its high 
uptake in cells.49 The reason for this is probably because of its ability to intercalate with or 
distort DNA. The activity of hypericin is oxygen dependant and this suggests that both the Type I   
(generation  of  reactive  oxygen  species)  and  Type  II  (generation  of  singlet  oxygen) 
mechanisms of photodynamic action are involved.50 For total necrosis of cells a high light dose 
needs  to  be  applied  which  is  typically  long  wavelength  red  light  to  aid  deeper  cell 
penetration.50 The high affinity hypericin has for cellular uptake makes it interesting for the 
treatment of other diseases or infections where cellular penetration of the agent is 
advantageous, however there has been very little research conducted as to whether hypericin 
has any antimicrobial function, or in particular antifungal action. 
 
Many synthetic analogues of hypericin have been produced in recent research for a variety of 
reasons including: improved physiochemical properties,51 enhanced interaction with DNA,52 
better  solubility  and  accumulation  in  desired  tissues.53,54    Much  of  the  work  has  been 
conducted by Falk and his co-workers who are renowned in this particular field, particularly 
with their new class of hypericin derivatives containing extra heterocyclic rings,55-57  but it is 
their work on the amino functionalised derivatives which gives particular promise due to 
excellent yields and enhanced solubility.37    Most of the research to date has focused on the 
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functionalisation of hydroxyl groups in the bay region of hypericin and the biological activity of 
 
derivatised peri hydroxyl groups has been largely overlooked (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bay positions 
Peri positions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peri positions 
 
 
Figure 5 Hypericin showing the bay and peri positions 
 
 
 
 
 
1.1.5 Anthraquinones 
 
The major building block of Hypericin is anthraquinone. This molecule is a three membered 
ring with keto groups at the 9th and 10th positions (Figure 6) although there can be many other 
functional groups attached to the other positions around the rings. As well as hypericin being 
made  up  from  anthraquinone,  many  dyes  and  drugs  are  based  on  the  anthraquinone 
structure,  for  example  rubiadin  extracted  from  Morinda  officionalis  (Figure  7).56-58    The 
synthesis of anthraquinone is a simple oxidation of anthracene using chromium(VI),59 but it can 
also be produced via a Friedel-Crafts reaction between benzene and phthalic anhydride.60 
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Figure 6 The structure of Anthraquinone 
 
 
 
 
 
 
 
 
Figure 7 Mechanism showing the synthesis of Anthraquinone 
 
 
 
 
There are many medical uses of anthraquinone based molecules: laxatives (dantron and 
emodin),65,61 antimalarials (rufigallol)62 and as antineoplastics used in the treatment of cancer 
(mitoxantrone and pixantrone)63,64 (Figure 8). 
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1          2 
3 
 
 
4 5 
 
 
Figure 8 The structures of Rubiadin (1), Dantron (2), Rufigallol (3), Mitoxantrone (4) and Pixantrone (5) 
 
 
 
 
One  of  the  most  recent,  promising  applications  of  an  anthraquinone  derivative  is  as  an 
inhibitor of Tau aggregate formation and as a solvent of paired helical filaments, both of which 
are considered to be significant to Alzheimer’s disease progression, and this has so far been 
shown in both mouse models and in vitro testing.65  Anthraquinones have also shown 
antioxidant activity in food,66  antiviral activity and have also been used in paper pulp 
manufacture of the raw materials for speciality paper.67,68 
 
1.1.6 Anthrones and Bianthrones 
 
Bianthrones are a class of compounds where two anthraquinones are joined via a linker or an 
immediate bond and they are an intermediate between anthraquinones and hypericin, (Figure 
9).  They  can  be   found  in  the  natural  world  in   Alternariaporri,69    Cassia  hirsuta  and 
 
Sennamultiglandulosa.70,71  Much of the research into bianthrones has focused on the linked 
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variety with applications ranging from intercalating agents,72,73 new generation antibiotics and 
electrochemically switched ion binders.74,75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 The structure of Bianthrone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Mechanism showing the synthesis of Bianthrone 
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1.1.7 Mechanism of Action of Antifungal Agents 
 
Almost all antifungal agents today take on the role of being either fungistatic or fungicidal. If 
an agent restricts the ability of the fungi to grow then it is termed fungistatic, much like when 
they are refrigerated, the fungi are preserved keeping them alive for long term storage or 
further study, or just to inhibit growth. Fungicidal means the killing of all fungi. Other forms of 
fungicidal  activity  are  the  use  of  heat,76   electromagnetic  or  ultraviolet  radiation  and  also 
exposure to chemicals.77-78  The term fungicidal generally refers to antifungals which show no 
 
further growth at concentrations equal to and greater than the Minimum Inhibitory 
Concentration (MIC) and all others which will show further growth at the MIC and above are 
termed fungistatic. However most antifungal agents will have a concentration at which they 
become fungicidal even if this concentration is much greater than the MIC.79 
 
Cell death occurs in one of two ways: apoptosis, the regulated process which is programmed 
and is led by biochemical events, and necrosis, which is the premature death of cells led by 
external factors; both are shown in Figure 11 below.80 It is thought that programmed cell death 
has evolved to regulate growth and development in unicellular organisms as well as 
multicellular organisms.81  Apoptosis is a process for removing unnecessary, damaged or aged 
cells and can be initiated by a number of intra- or extracellular factors. Dying cells undergo a 
distinct set of structural changes, which are characteristic to apoptosis and are typically: 
shrinkage, membrane blebbing, chromatin condensation and DNA fragmentation and finally 
formation of apoptotic bodies, which are ingested by surrounding cells. Cellular content is 
never exposed to the immune system minimising inflammatory reactions.82  Necrosis, by 
contrast, occurs due to external physical or chemical insult and is characterised by swelling of 
the entire cytoplasm and organelles which causes the membrane to burst. This results in 
spillage of the cellular components, ultimately resulting in inflammatory response.80 
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In unicellular organisms, like yeast, cell death always takes place via apoptosis and can occur 
during development, ageing and reproduction, but it can also be brought on by environmental 
trauma and contact with toxic agents.83-87 
 
Malignant cells are often incapable of triggering apoptosis, so the selective activation of the 
process is an increasingly attractive therapeutic target. Hypericin has been shown to induce 
apoptosis in cultured human malignant glioma cells and was followed shortly by other cell 
lines.88-97 The conditions used had been poorly defined until the work of Miccoli et al in 1998,89 
closely followed by others, which confirmed that under controlled irradiation of different 
tumour cell lines with hypericin there follows activation of the apoptotic pathway.90-92 
 
 
 
 
Figure 11 The cell death pathways of necrosis and apoptosis.93 
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1.2 Rationale 
 
 
Outlined below are the synthetic routes taken for the synthesis of hypericin derivatives, 
anthraquinone derivatives and bianthrone derivatives. Also detailed is the suggested route to 
the determination of fungistatic and fungicidal activity of the compounds. 
 
1.2.1 Anthraquinones, Anthrones and Bianthrones 
 
The synthetic route to the anthraquinone, anthrone and bianthrone derivatives (Scheme 1 and 
Table 1) all start with 1,8-dihydroxyanthraquinone (1,8-DHA). For the various anthraquinones 
either one or both the hydroxyl groups on the 1,8-DHA is protected with a tosyloxy group using 
the protecting reagent 4-toluenesulphonyl chloride (p-TsCl) under basic conditions using 
dichloromethane (DCM) as solvent. The ditosylated anthraquinone is then treated with either 
ethylenediamine, trimethylenediamine or putrescine to create the aminated anthraquinones. 
For the synthesis of the anthrones the 1,8-DHA and the tosylated anthraquinones have one of 
the keto groups reduced using tin(II) chloride (SnCl2) and concentrated hydrochloric acid in 
acetic acid and these are then irradiated in the microwave to produce the bianthrones using 
potassium tert-butoxide (t-BuOK) to deprotonate the methylene on the central ring. 
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Scheme 1 The synthetic route 
 
Table 1 Table showing compound functionality 
 
 
Compound 
 
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
 
R1 
NHC2 NHC3 NHC3 NHC4 
OTs OTs OH OH OTs OTs OH OH OTs OTs OH H4NH2 H6NH2 H6NH2 H8NH2 
 
R3 
 
H H OH H H H OH H H H H H H H H 
 
R6 
 
H H CH3 H H H CH3 H H H H H H H H 
 
R8 
 
OH OTs OH OH OH OTs OH OH OH OTs OH OH OH OTs OTs 
 
R9 
 
OH OH OTs OTs OTs 
 
R11 
 
OH H H H H 
 
R14 
 
CH3 H H H H 
 
R16 
 
OH OH OH OTs OTs 
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1.2.3 Determination of Antifungal Activity 
 
Three strains of yeast will be used to test, first for the toxicity of the compounds made and 
then for their fungistatic and fungicidal affects. The three strains of yeast to be used are 
Schizosaccharomyces pombe (S. pombe), Lipomyces starkeyi (L. starkeyi) and Saccharomyces 
cerevisiae (S. cerevisiae). These have been chosen because they have been demonstrated to be 
good representative yeast species and they are non-pathogenic.1 Therefore, their use in 
antifungal susceptibility testing and in the screening of chemical libraries for fungicidal effects 
is advantageous because it reduces exposure to pathogenic fungi.94  The first step will involve 
the determination of solubility for each of the compounds being tested: it is hoped that the 
compounds will be water soluble, but if this is not the case then dimethyl sulfoxide (DMSO) 
will be used to dissolve the compounds as this is known to be non-toxic up to 10% 
concentration.95   For  this  0.01g  of  the  compound  will  be  treated  with  100µl  of  media 
repeatedly until the compound dissolves. If there is no solubility in the media then the process 
will be repeated in DMSO. Once all the compounds are dissolved they will then be introduced 
to the yeast strains using serial dilutions and then left to grow overnight. This will be done by 
transferring 3 x 104 yeast cells into each well of a 96-well microtitre plate. The compound will 
then be transferred into the first column of the plate and then a 1:2 serial dilution will be 
performed down the row. This will be repeated for each compound, in each yeast, in duplicate. 
If there is growth in the cell then the compound concentration will be determined to be non- 
growth inhibitive, but if there is no growth then the compound concentration will be 
determined as growth inhibitive. The wells with inhibitive concentrations will then be diluted 
down in 50 ml of media to ensure the compound is strongly diluted, and left to incubate for 16 
hrs with shaking at 200rpm at 30°C to see if any growth will occur. If there is growth of yeast 
present then the compound can be determined as fungistatic; if there is no growth of yeast 
then this suggests the compound is fungicidal. There were no comparisons made. 
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CHAPTER 2. RESULTS AND DISCUSSION 
 
 
 
 
 
 
2.1 Synthesis of Compounds 
 
 
Including the two anthraquinones purchased from Sigma Aldrich (Emodin and 1,8-DHA), six 
pure  1,8-substituted  anthraquinone  compounds  were  synthesised.  These  fitted  into  two 
categories, the tosyloxy and amino substituted anthraquinones. 
 
 
 
 
 
(i ) Ts Cl , Et3N, DCM 
(i i ) R-NH2, DCM 
 
 
(i )                    (i i ) 
 
 
1.  R1 = OH,   R8 = OH 
3.  R1 = OH,   R8 = OTs 
4.  R1 = OTs , R8 = OTs 
 
 
 
 
 
14. R1 = OH,   R8 = NHC2H4NH2 
15. R1 = OH,   R8 = NHC3H6NH2 
16. R1 = OTs , R8 = NHC3H6NH2 
17. R1 = OH,   R8 = NHC4H8NH2 
 
 
Scheme 2 The anthraquinone synthesis 
 
 
 
 
The synthetic pathway as seen in Scheme 2 shows the route to the tosyloxy protected 
anthraquinones. This resulted in two pure compounds, the first of which 1-hydroxy-8- 
tosyloxyanthraquinone (3) was produced in reasonable yield (30%) and of excellent purity as 
judged by the 1H NMR spectrum (Figure 12). This was done using a 4:3 stoichiometric ratio of 
1,8-DHA to p-TsCl. After removal of the excess 1,8-DHA using solvent extraction, purification 
 
via  column  chromatography  using  silica  gel,  isolated  the  product  as  a  fine,  bright  yellow 
powder. 
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Figure 12 NMR spectrum of 1-hydroxy-8-tosyloxyanthraquinone (3). 
 
 
 
 
The second compound, 1,8-ditosyloxyanthraquinone (4), was produced in good yield (61%) 
and outstanding purity as judged by the 1H NMR spectrum (Figure 13). This was accomplished 
using a 10:1 stoichiometric ratio of p-TsCl.  The pure compound being isolated after the excess 
p-TsCl was removed using boiling petroleum ether.  This yielded the pure compound as a fine, 
pale flaxen brown coloured powder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 NMR spectrum of 1,8-ditosyloxyanthraquinone (4). 
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Four pure compounds were synthesised from the starting materials of 1,8- 
ditosyloxyanthraquinone (4) and the amines ethylenediamine, trimethylenediamine and 
putrescine. This was possible due to 4-toluenesulphonate being a highly stable leaving group 
with a distributed negative charge (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 The resonance structures of 4-toluenesulphonate. 
 
 
 
 
1-[(2-Aminoethyl)amino]-8-hydroxyanthraquinone (14) was produced in a reasonable yield 
(34%) with ethylenediamine on a 1:1 ratio with compound 4. The 1H NMR spectrum (Figure 15) 
shows the methylene chain triplets present implying the synthesis was successful. The product 
was produced as black crystals and a bright pink solution was observed on addition of 
chloroform (CHCl3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 NMR spectrum of 1-[(2-aminoethyl)amino]-8-hydroxyanthraquinone (14). 
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The second amine, trimethylenediamine, gave two pure products after purification by column 
chromatography from one reaction, both of which gave the two triplets and quintet from the 
methylene chain in their 1H NMR spectra (Figures 16 and 17). The first compound 1-[(3- 
aminopropyl)amino]-8-hydroxyanthraquinone (15), lost the extra tosyloxy group to leave a 
hydroxyl group and gave a dark purple powder which turned into a bright purple solution on 
addition of CHCl3. The second compound 1-[(3-aminopropyl)amino]-8-tosyloxyanthraquinone 
(16) retained the tosyloxy group at position 8 and gave a dark red powder which turned into a 
bright pink solution on addition of CHCl3. 
 
 
 
 
Figure 16 NMR spectrum of 1-[(3-aminopropyl)amino]-8-hydroxyanthraquinone (15). 
 
 
 
 
 
 
 
Figure 17 NMR spectrum of 1-[(3-aminopropyl)amino]-8-tosyloxyanthraquinone (16). 
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The third amine used, putrescine, gave 1-[(4-aminobutyl)amino]-8-hydroxyanthraquinone (17). 
This product showed two triplets and two quintets for the methylene chain in the 1H NMR 
spectrum (Figure 18) and gave a dark purple powder which turned into a bright purple solution 
on addition of CHCl3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 NMR spectrum of 1-[(4-aminobutyl)amino]-8-hydroxyanthraquinone (17). 
 
 
 
 
 
The anthraquinone compounds were produced in mostly reasonable yields and of excellent 
purity. The tosylation reactions worked with fantastic results and were relatively easy to work 
up, but they were difficult to reproduce on a large scale. Purification of the substituted amine 
derivatives using column chromatography was tedious requiring on occasion two or more 
attempts. The reaction itself was straightforward,  however, only needing approximately 2 
hours to complete. 
 
The next group of compounds in the synthesis of hypericin derivatives, the anthrones, were 
produced by reducing the carbonyl group chemo-selectively at the 10th  position with SnCl2  in 
the presence of concentrated hydrochloric acid and acetic acid and the reduction was then 
followed up by a simultaneous acid hydrolysis as shown in Scheme 3. In addition to the two 
tosyloxy compounds, emodin and 1,8-DHA were also reduced to give four pure compounds. 
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(i) 
 
 
 
 
 
(i) Sn(II)Cl, Conc. HCl, CH3CO2H 
 
5. R1 = OH, R3 = CH3, R6 = OH, R8 = OH 
6. R1 = OH, R3 = H, R6 = H, R8 = OH 
 
7. R1 = OTs, R3 = H, R6 = H, R8 = OH 
8. R1 = OTs, R3 = H, R6 = H, R8 = OTs 
 
 
Scheme 3 The anthrone synthesis. 
 
 
 
 
The first: emodin anthrone (5) is the reduced form of emodin and this was synthesised as a 
pale green powder in excellent yield (91%), showing the signature singlet at 4.313ppm on the 
1H NMR spectrum (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 NMR spectrum of emodin anthrone (5). 
 
 
 
The next compound, 1,8-dihydroxyanthrone (6), was produced as a buff coloured powder in 
superb yield (91%) and showed the singlet on the 1H NMR spectrum at 4.472ppm (Figure 20). 
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Figure 20 NMR spectrum of 1,8-dihyroxyanthrone (6). 
 
 
 
 
The next two compounds gave slightly lower yields at 82% for 1-hydroxy-8-tosyloxyanthrone 
(7)  and  79%  for  1,8-tosyloxyanthrone  (8).  Both  were  chartreuse  coloured  powders  with 
singlets present in the 1H NMR spectra at 3.982ppm and 4.313ppm respectively. 
 
The bianthrones followed a different synthetic route to the one shown in Scheme 1 originally, 
which involved an oxidative coupling using iron(III) chloride hydrate in ethanol as seen in 
Scheme 4. This method resulted in a very poor yield (<15%), so another method was found 
using microwave synthesis and t-BuOK in dimethylformamide (DMF). This method greatly 
improved the process giving five compounds with yields of between 90% at the highest to 32% 
at the lowest, but was also a much greener method towards the synthesis. 
 
 - 24 
 
 
 
 
 
 
 
 
 
 
 
 
(i) 
 
(ii) 
 
 
Route 1.(i) Fe(III)Cl, C2H5OH 
Route 2.(ii) K-t-butoxide, DMF 
 
9. R1 = OH, R3 = CH3, R6 = OH, R8 = OH, R9 = OH, R11 = CH3, R14 = OH, R16 = OH 
10. R1 = OH, R3 = H, R6 = H, R8 = OH, R9 = OH, R11 = H, R14 = H, R16 = OH 
11. R1 = OTs, R3 = H, R6 = H, R8 = OH, R9 = OTs, R11 = H, R14 = H, R16 = OH 
12. R1 = OTs, R3 = H, R6 = H, R8 = OTs, R9 = OTs, R11 = H, R14 = H, R16 = OTs 
13. R1 = OH, R3 = H, R6 = H, R8 = OH, R9 = OTs, R11 = H, R14 = H, R16 = OTs 
 
 
Scheme 4 The bianthrone synthesis. 
 
 
 
 
Emodin bianthrone (9) gave black crystals at 67% yield and when dissolved in CHCl3 gave a 
solution with an intense purple colour. The oxidative coupling across the centre went to the 
double bond, which was seen through the loss of the singlet in the 1H NMR spectrum at 
4.313ppm in the starting material. 1,8,9,16-tetrahydroxybianthrone (10) had the best yield at 
 
90% of a saffron coloured powder. Only the single bond was achieved with a singlet still 
present at 4.327ppm in the 1H NMR spectrum (Figure 21), this is distinguishable from the 
anthrone due to the integration being for just 1 proton. 
 
 
 
Figure 21 NMR spectrum of 1,8,9,16-tetrahydroxybianthrone (10). 
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The next compound 1,9-dihydroxy-8,16-ditosyloxybianthrone (11) gave a brown powder with a 
yield of 80% and again only had the single bond due to the singlet at 4.349ppm present in the 
1H NMR spectrum. The last two compounds, 1,8,9,16-tetratosyloxybianthrone (12) and 1,8- 
 
dihydroxy-9,16-ditosyloxybianthrone (13) both gave red coloured powders with compound 
(13) being slightly darker. The yields were 82% and 32% respectively and both have the double 
bond as shown by the lack of the singlet around 4ppm in their 1H NMR spectra (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 NMR spectrum of 1,8,9,16-tetratosyloxybianthrone (12) 
 
 
 
 
 
The procedure for synthesising the anthrones and the bianthrones gave pure products in 
reasonable to excellent yields. Although the tin(II) chloride reduction for the anthrones was 
time consuming, needing to run for approximately 12 hours, the reaction worked favourably 
with good yields and the precipitate which resulted in the work up needed no further 
purification. 
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The microwave synthesis improved the reaction time of the bianthrones to just 30 minutes 
instead of the 5 hours stated in the previous method and the work-up was much simpler, 
giving a near pure product in the initial precipitate, with only two of the compounds needing 
further purification by column chromatography. Although two of the compounds (10 and 11) 
gave just the single bond connecting the central rings, when the compounds were put back on 
to react further, the double bond could not be obtained and they remained as just the single 
bonded products. 
 
2.2 Antifungal Results 
 
 
Three types of yeast were used for the determination of growth inhibition: S. pombe, a fission 
yeast  used  in  eukaryotic  microbiological  research;  S.  cerevisiae,  a  budding  yeast;  and  L. 
starkeyi, an oleaginous budding yeast from the same genetic tree as S. cerevisiae. 
 
All the compounds used for testing were compared against hypericin as a standard. The Table 
of data and the annotated pictures of the plates can be found in the Appendix. 
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Figure   23    Minimum     Inhibitory    Growth    Concentration     (MIC}   of   synthesised    compounds    tested     in 
Schizosocchoromyces pombe. Cells were inoculated  ot o concentration of 3 x 10  /ml. Culture media ested were in 
yeast extract broth (YE).Growth of yeast was determined visually after 24 hours of incubation  at 30 C. The MIC of 
the com pounds  was d etermined to be the well be fore yeast growth  was first seen. The experiment was re peated 
three  times  to ensure reproducibility  of the results. Compound s were determined to be fungicidal (red bars ), if no 
gro wth  was observed and  fungistatic  (green  bars}, if normal  growth  was  seen  after  inoculation into  fresh YE 
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Figure 24 Minimum  Inhibitory Growth Concentration {MIC) of synthesised compounds tested  in Upomyces  starkeyi. 
Cells were inoculated  at a concentration of 3 x 10 /ml.Culture med!a tested  were in yeast extract broth (YE).Growth 
of yeast was determined visually after 24 hours of incubation  at 30 C. The MIC of the compounds was determined to 
be the well before  yeast growth was first seen. The experiment was repeated  three times  to ensure  reprod ucibilit y of 
the  results. Compound s were  determined to be  f un gicidal ( red bars ), if no  growth   was observed  and  fungistatic ( 
green bars ), if normal growth  was seen after inoculation into fresh Y E media. 
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Figure 25 Minimum  Inhibitory Growth  Concentration  (MJC) of synthesised compounds tested  in Saccharomyces 
cerevisiae. Cells were inoculated  at a concentration of 3 x 10  /ml.Culture media tested  were in yeast extract broth 
(YE). Growth of yeast was determined visually after 24 hours of incubation at  3a·c. The MIC of the compounds was 
determined to be the well before  yeast growth  was first seen. The experiment was repeated  three times  to ensure 
reproducibility of the results. Compounds  were determined to be fungicidal (red bars), if no growth  was observed 
and fungistatic (green bars), if normal growth was seen after inoculation into fresh YE media. 
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The anthraquinones showed varied results between the yeast strains. In the S. pombe they 
were  consistently  inhibitive  at  a  concentration  greater  than  1mM.  In  the  L. starkeyi,  the 
emodin and 1,8-DHA were inhibitive at concentrations greater than 2.5 and 2.9 mM, 
respectively, but 1-hydroxy-8-tosyloxyanthraquinone (3) and 1,8-ditosyloxyanthraquinone (4) 
suggested that these compounds protected the yeast cells against the DMSO in which they 
were dissolved, as growth could be seen in the 1st  lane which contained DMSO to a 
concentration of 10%, known to be inhibitive to growth. In the S. cerevisiae the results were 
varied, with emodin and compound (3) having similar results to that of the S. pombe, 1,8-DHA 
showed the same result as for L. starkeyi and compound (4) had a reduced inhibitive 
concentration of 0.638nM. 
 
All the compounds, except compounds (3) and (4) in L. starkeyi which were not tested due to 
being non-growth inhibitive, this can be seen in the growth present in the well containing a 
toxic concentration of DMSO, showed growth after removal of the product suggesting that 
they are fungistatic. 
 
The amine anthraquinone compounds all had growth inhibition concentrations at greater than 
 
0.1nM but less than 1nM. The concentrations for L. starkeyi and S. cerevisiae were higher than 
those for S. pombe, except for 1-[(4-aminobutyl)amino]-8-hydroxyanthraquinone (17) in S. 
cerevisiae which was equal. In the antifungal tests for S. pombe, 1-[(3-aminopropyl)amino]-8- 
hydroxyanthraquinone (15) and compound (17) were fungicidal and 1-[(2-aminoethyl)amino]- 
8-hydroxyanthraquinone  (14)  and  1-[(3-aminopropyl)amino]-8-tosyloxyanthraquinone  (16) 
 
were fungistatic. In both the L. starkeyi and S. cerevisiae all the compounds except (16) were 
fungistatic. 
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Figure 26 The results for the compounds which showed  different  results for the different yeast strains. For each of 
the  compounds the  1st  column  shows  the  MIC for 5. pombe, the 2nd  column  for L. starkeyi  and the  3rd  for 5. 
cerevisiae. The  fungistatic  compounds are denoted  by  a green  column  and  the  fungicidal compounds by  a red 
column. 
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The growth inhibition concentrations for the anthrones in S. pombe were all consistently under 
 
0.1mM, which is similar to those for S. cerevisiae, except for emodin anthrone (5), which is at 
 
1.95mM. In the L. starkeyi compound 5 and 1,8-dihydroxyanthrone (6) were both significantly 
less growth inhibitive with concentrations of 39mM and 22.1mM respectively, but 1-hydroxy- 
8-tosyloxyanthrone (7) and 1,8-ditosyloxyanthrone (8) gave similar results to these of S. pombe 
and S. cerevisiae. With S. pombe all the compounds were seen to be fungistatic, but in both L. 
starkeyi and S. cerevisiae all but compound (5) were fungistatic, which itself was fungicidal. 
 
One of the bianthrones stood out from all the others, 1,8,9,16-tetratosyloxybianthrone (12) 
did not show any growth inhibition concentration and, like compounds (3) and (4) with L. 
starkeyi, seemed to protect the cells against the growth inhibitive effect of the DMSO. The 
case could be however that the DMSO aided the membrane transport of the compound inside 
the yeast cells and it was the presence of the DMSO which altered the inhibitive effects of the 
compound.95  For all the other compounds the growth inhibition concentrations were similar. 
Emodin bianthrone (9) had the same growth inhibition concentration for all of the yeasts, 
1,8,9,16-tetrahydroxybianthrone (10) and 1,8-dihydroxy-9,16-ditosyloxybianthrone (13) were 
less growth inhibitive for both L. starkeyi and S. cerevisiae. 1,9-Dihydroxy-8,16- 
ditosyloxybianthrone (11) was less growth inhibitive for just the L. starkeyi. All the compounds: 
except compound (12) which was not tested (again this can be seen by the growth present in 
the well containing a toxic concentration of DMSO similar to compounds (3) and (4) in L. 
starkeyi) and compound (13) which was fungicidal for S. pombe, were found to be fungistatic 
for all of the yeasts. 
 
Of all the compounds tested, hypericin was the only one to show it had less growth inhibitive 
effect for S. pombe than the L. starkeyi and S. cerevisiae. Only two of the compounds 
synthesised came close with compound (9) having equal growth inhibitive concentrations for 
all of the yeasts and compound (12) which was non-growth inhibitive in all the yeast strains. 
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This is most probably due to the increased lipophilic nature of the compounds; increased 
lipophilicty will aid the membrane crossing of the compound and if the compound is present 
within the cell rather than just in the locality it is more likely to have an effect on the yeast cell. 
It  is  therefore  beneficial  to  concentrate  on  the  most  lipophilic  compounds  due  to  the 
possibility of membrane crossing and develop them to be more responsive to fungi rather than 
human cells. 
 
Initially, it was expected that the tosyloxy substituted compounds would show more growth 
inhibition (because of the toxic nature of the starting material)96,97  than the hydroxyl and 
amine  substituted  compounds,  because  tosyloxy  compounds  with  more  tosyloxy  groups 
present increase the growth inhibition. This was shown to be the case in the anthraquinone 
and anthrone compounds (3), (4), (7) and 98) which all showed a more inhibitive effect on the 
growth of yeast than the hydroxy and amino substituted compounds. With the bianthrone 
compounds (11), (12) and (13), however, it was discovered that the more tosyloxy groups that 
were substituted on the molecule, the less inhibited was the growth of the yeast. 
 
This was the complete opposite of the anthraquinones where, aside from in L. starkeyi, more 
tosyloxy groups increased the growth inhibition of the yeast. In the anthrone group the 
compounds with increasing number of tosyloxy groups increased the growth inhibition in both 
the L. starkeyi and S. cerevisiae, but in the S. pombe, the difference between the growth 
inhibition concentrations was insignificant. 
 
In the amino anthraquinones it was found that the shorter the methylene chain between the 
amino groups, the less growth inhibition was shown, and this is true for all the yeast strains. It 
was also observed that the presence of the tosyloxy group in compound (16) reduces the 
growth inhibition in comparison to compound (15), where the tosyloxy group at position 8 on 
the molecule is the only difference between the two compounds. 
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Due to the close genetic relationship between L. starkeyi and S. cerevisiae the antifungal 
results were expected to show similarity for these two yeast strains and for S. pombe to show 
the opposite result was not totally unexpected, as although it is from the same family of yeast 
it does not share as close a genetic relationship as the other two yeasts.98,99 One possible 
explanation for this could be that the majority of the compounds show fungistatic properties, 
as they are more organic in nature with tosyloxy groups and methylene chains. This would be 
preferable for the L. starkeyi due to its ability to accumulate lipids and therefore a 
predisposition towards more organic substances.100  As S. cerevisiae is similar genetically to L. 
starkeyi,98 this explains the parallel results. 
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CHAPTER 3. CONCLUSIONS AND FUTURE WORK 
 
 
 
 
3.1 Conclusions 
 
 
The anthraquinone derivatives were developed in a straightforward method according to the 
method of Schio, Chatreaux and Kilch.101  The tosylation reactions had been done many times 
previously, so this was a case of following the protocol and purifying the products formed, 
although an improvement was made in the work-up which involved getting a much cleaner 
product by heating it in hexane to remove most of the p-TsCl starting material due to it being 
less polar and therefore more soluble in the warm hexane than the product. The amine 
anthraquinones caused a few problems with an initial reaction plan involving long reaction 
times  and triethylamine  as  strong  base,  as  stated in  the  protocol  according to  Zielske,102 
possibly there for the purpose of activating the carbon with the tosyloxy group attached. As 
the tosyloxy group acts as a strong activating group in its own right,103 the use of triethylamine 
was abandoned. It was also discovered that the 250x excess of amine was extreme and so was 
scaled down to 4x excess and after this the further reactions proceeded in an improved 
behaviour and in much less time. 
 
The protocol leading to the synthesis of the anthrone derivatives as outlined by Motoyoshiya, 
Masue, Nishi and Aoyama in their paper on the synthesis of hypericin was relatively 
straightforward, so this was the method followed for the synthesis of the anthrone 
derivatives.43  These progressed with no problems and so no improvement could be made on 
their synthesis. As this method proceeded with pure products as the outcome from a very 
simple work-up, there was no need to tamper with the route. 
 
The initial protocol for the synthesis of the bianthrone compounds involving iron(III) chloride, 
also from the paper by Motoyoshiya, Masue, Nishi and Aoyama, was complicated and did not 
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yield much product; it also involved using a large amount of solvent for a small scale reaction, 
so it was not preferable.43  An improved method involving the microwave synthesis from the 
research by Aigner and Falk was done with minimal solvent and gave mostly pure product with 
little work-up.104 As developing newer, green methods are of major interest due to the 
importance   of   modern   synthetic   chemistry   being   more   environmentally   friendly;   this 
enhanced synthetic route is a most important improvement.105 
 
The results from the growth inhibition testing did not give the results expected. It was hoped 
that some of the compounds may be less inhibitive in S. pombe than L. starkeyi, but this was 
not the case for any of the compounds synthesised. The increased growth inhibition of the 
anthrone derivatives in S. pombe was unexpected with a possible reason being the increased 
organic nature of the molecules. 
 
Another reason could be the metabolism of the yeast; mostly this is done by aerobic 
respiration.106 However, some yeasts are able to ferment sugars such as glucose, producing 
ethanol and carbon dioxide even when there is oxygen available and this is known as the 
Crabtree effect.107,108 The balance between respiration and fermentation may increase the 
sensitivity of the yeast to the compounds therefore accounting for the increased growth 
inhibition in the anthrone derivatives.94 
 
It has been suggested that the mechanism by which antifungals affect yeast is by changing the 
physical properties of the yeast cell membrane, particularly the permeability, which could 
account for the differences in the growth inhibition for the compounds.109, 110  There is also 
evidence to suggest that quinone containing species can create reactive oxygen species and 
therefore induce lipid peroxidation of the yeast.111 
 
For the majority of the compounds to be fungistatic was unexpected, especially after the low 
growth inhibition concentrations of some of them, these would be expected to be fungicidal 
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due to the low concentrations of the compound needed to affect the yeast. However,  for the 
few compounds that were fungicidal in one of the yeasts, but not the others, this could also be 
due to the metabolism of the yeast tested. 
 
Looking at the functionality of the compounds there seems to be no consistency in whether 
they will be either fungistatic or fungicidal. 
 
3.2 Future Work 
 
 
There is much scope to continue work on this project in the future. The derivatives could be 
developed to hypericin-like compounds with all the bonds connected between the rings. There 
is also the possibility of creating more derivatives with enhanced features such as better water 
solubility, increased absorption into the near infrared and increased cellular uptake. 
 
The results of the growth inhibition assay show that the best amine to use to increase the 
water solubility is ethylenediamine as it did not become inhibitive towards growth until much 
greater concentrations than both the trimethylenediamine and putrescine. It would not be 
wise to rule out these amines completely; however, as when the molecules are taken to the 
anthrone and bianthrone this could influence the inhibitive effects. 
 
There are many different anthraquinones that can be studied, with a variety of different 
functional groups and the next step in this project would have been to synthesise some 
derivatives from 1,4-diyhdroxyanthraquinone, which is readily available. Another route would 
be to reduce 1,8-dinitroanthraquinone, which will cut out the protection / activation step with 
p-TsCl and possibly reduce the growth inhibitive effect again. This could be to a distinct 
advantage if it is to be believed that the shorter the methylene chain between the amines the 
lower effect on growth inhibition of the yeast, then no chain present should be a distinct 
advantage. 
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Another possibility  for future  research would  be using the resorufin  fluorescence inhibition 
technique outlined  by Fai et al,94 this would provide a greater sensitivity to the result of the 
inhibition assay and also an insight to the general metabolism of the yeast. 
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CHAPTER 4. SYNTHESIS AND EXPERIMENTAL 
 
 
 
 
4.1 Chemical Synthesis 
 
 
1H NMR spectra were measured on a Bruker Avance 400MHz spectrometer, δ values are 
quoted relative to tetramethylsilane (TMS, δH 0.00ppm). Mass spectra were recorded on a 
Thermo Scientific Trace LC Ultra DSQ II using Electron Impact Ionisation (LCMS-EI). The Ultra 
Violet absorptions were recorded on a WPA Lightwave II UV/Visible spectrophotometer. 
Infrared spectra were recorded on a Specac ATR with a He/Ne 633nm laser. Thin Layer 
Chromatography (TLC) was carried out on Machery-Nagel polygramSil/G/UV254 pre-coated 
plates. All chemicals, solvents and silica gel were obtained commercially from either Sigma 
Aldrich or Alfa Aesar and used without further purification. 
 
Emodin (1), 1,8-DHA (2) and Hypericin (18) were obtained from Sigma Aldrich to be used for 
testing alongside the synthesised molecules below. 
 
1.   Synthesis of 1-hydroxy-8-tosyloxyanthraquinone (3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1,8-DHA  (9.61g,  0.04mols)  in  DCM  (100cm3)  was  stirred  in  an  ice  bath  for  10  mins. 
Triethylamine (TEA) (4.05g, 0.04mols) and p-TsCl (5.72g, 0.03mols) were added slowly to the 
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reaction flask to ensure the reaction did not exceed 40°C for 6 hours. The reaction mixture was 
extracted with DCM (50cm3) and the organic layer was washed with 2M hydrochloric acid (HCl) 
(6 x 50cm3). The organic layer was isolated, dried with anhydrous sodium sulphate and the 
solvent removed under pressure. The resulting solid was heated in hexane (50cm3) and filtered 
under pressure. The crude product was then purified by silica column chromatography eluting 
with CHCl3  to give the pure product as the second band (Rf  = 0.68). The 1-hydroxy-8- 
tosyloxyanthraquinone was obtained as a yellow powder, yield 4.63g, 29.3%, 1H NMR (CDCl3, 
400MHz) δppm 2.42 (s, CH3, 3H), 7.29 (dd, J = 8Hz, J = 1Hz, Ar-H, 1H), 7.31 (d, J = 8Hz, Ar-H, 
 
2H), 7.55 (dd, J = 8Hz, J = 1Hz, Ar-H, 1H), 7.64 (t, J = 8Hz, Ar-H, 1H), 7.76 (t, J = 8Hz, Ar-H, 1H), 
 
7.77 (dd, J = 8Hz, J = 1Hz, Ar-H, 1H), 7.81 (d, J = 8Hz, Ar-H, 2H), 8.29 (dd, J = 8Hz, J = 1Hz, Ar-H, 
 
1H), 12.38 (s, OH, 1H). IR (ATR) 2000, 1699, 1380, 1180, 980, 870, 750, 650, 550 cm-1. MS-EI: 
 
393.03 [M+]. UV abs λ max = 247nm. 
 
 
 
 
2.   Synthesis of 1,8-ditosyloxyanthraquinone (4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1,8-DHA (5.00g, 0.02mols) in DCM (120cm3) was stirred in an ice bath for 10mins. TEA (25.30g, 
 
0.25mols) and p-TsCl (43.80g, 0.23mols) were added slowly to the reaction flask to ensure the 
reaction did not exceed 40°C for 6 hours. The reaction mixture was  extracted with DCM 
(50cm3) and the organic layer was washed with 2M HCl (6 x 50cm3). The organic layer was 
isolated, dried with anhydrous sodium sulphate and the solvent removed under pressure. The 
resulting solid was heated in hexane (50cm3) and filtered under reduced? pressure. The crude 
product was then purified by silica column chromatography eluted with CHCl3 to give the pure 
 
 -  41 - 
 
product as the second band (Rf  = 0.62). This yielded 1,8-ditosyloxyanthraquinone as a pale 
flaxen powder, 13.32g, 60.7%, 1H NMR (CDCl3, 400MHz) δppm 2.41 (s, CH3, 3H), 7.33 (d, J =8Hz, 
Ar-H, 2H), 7.65 (dd, J =8Hz, J = 1Hz, Ar-H, 1H), 7.71(t, J = 8Hz, Ar-H, 1H), 7.92 (d, J = 8Hz, Ar-H, 
2H), 8.17 (dd, J = 8Hz, J = 1Hz, Ar-H, 1H). IR (ATR) 1380, 1180, 980, 860, 750, 680, 570, 560 cm- 
 
1. MS-EI: 548.94 *M++. UV abs λ max = 250nm. 
 
 
 
 
3.   Synthesis of emodin anthrone (5) 
 
 
 
 
 
 
 
 
 
 
 
A warm solution of SnCl2 (0.35g, 1.83mmols) in conc. HCl (3cm3) was added to a suspension of 
emodin (0.05g, 0.183mmols) in acetic acid (AcOH) (5cm3) and the reaction mixture was left to 
stir under reflux for 15 hours. The reaction mixture was allowed to cool and poured slowly into 
ice water, which resulted in the isolation of emodin anthrone as a pale green powder, yield 
 
0.043g, 91.5%,1H NMR (DMSO, 400MHz) δppm 2.33 (s, CH3, 3H), 4.31 (s, CH2, 2H), 6.23 (s, Ar-H, 
 
1H), 6.43 (s, Ar-H, 1H), 6.68 (s, Ar-H, 1H), 6.79 (s, Ar-H, 1H), 10.84 (s, OH, 1H), 12.24 (s, OH, 1H), 
 
12.39 (s, OH, 1H). IR (ATR) 3300, 1600, 1490, 1290, 1240, 1150, 1070, 800, 770, 690, 550 cm-1. 
MS-EI: 257.76 [M++. UV abs λmax = 224nm. 
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4.   Synthesis of 1,8-dihydroxyanthrone (6) 
 
 
 
 
 
 
 
 
 
 
 
A warm solution of SnCl2 (1.07g, 4.78mmols) in conc. HCl (5.5cm3) was added to a suspension 
of 1,8-DHA (0.12g, 0.478mmols) in AcOH (10cm3) and the reaction mixture was left to stir 
under reflux for 24 hours. The reaction mixture was allowed to cool and poured slowly into ice 
water, which resulted in the isolation of 1,8-dihydroxyanthrone as a buff powder, yield 0.10g, 
 
90.9%, 1H NMR (DMSO, 400MHz) δppm 4.31 (s, CH2, 2H), 6.90 (d, J = 8Hz, Ar-H, 2H), 7.03 (d, J = 
 
8Hz, Ar-H, 2H), 7.61 (t, J = 8Hz, Ar-H, 2H), 12.09 (s, OH, 2H). IR (ATR) 3000, 2150, 1600, 1450, 
 
1280, 1200, 780, 700, 620 cm-1. MS-EI: 226.18 *M++. UV abs λ max = 226nm. 
 
 
 
 
5.   Synthesis of 1-hydroxy-8-tosyloxyanthrone (7) (NOVEL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A warm solution of SnCl2 (5.69g, 0.03mols) in conc. HCl (30cm3) was added to a suspension of 
compound (3) (1.18g, 3.0mmols) in AcOH (60cm3) and the reaction mixture was left to stir 
under reflux for 48 hours. The reaction mixture was allowed to cool and poured slowly into ice 
water,  which  resulted  in  the  isolation  of  1-hydroxy-8-tosyloxyanthrone  as  a  chartreuse 
powder, yield 0.93g, 81.6%, 1H NMR (CDCl3, 400MHz) δppm 2.33 (s, CH3, 3H), 3.98 (s, CH2, 1H), 
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7.16 (d, J = 8Hz, Ar-H, 2H), 7.26 (d, J = 8Hz, Ar-H, 1H), 7.39 (dd, J = 8Hz, J = 2Hz, Ar-H, 1H), 7.41 
(t, J = 8Hz, Ar-H, 1H), 7.55 (t, J = 8Hz, Ar-H, 1H), 7.78 (d, J = 8Hz, Ar-H, 1H), 7.88 (d, J = 8Hz, Ar- 
H, 1H), 8.24 (dd, J = 8Hz, J = 2Hz, Ar-H, 1H), 12.52 (s, OH, 1H). IR (ATR) 3000, 1600, 1490, 1460, 
1370, 1280, 1250, 1170, 730, 620, 550 cm-1. MS-EI: 380.76 [M++. UV abs λ max = 224nm. 
 
 
 
 
6.   Synthesis of 1,8-ditosyloxyanthrone (8) (NOVEL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A warm solution of SnCl2 (5.69g, 0.03mols) in conc. HCl (30cm3) was added to a suspension of 
compound (4) (1.64g, 3.0mols) in AcOH (60cm3) and the reaction mixture was left to stir under 
reflux for 48 hours. The reaction mixture was allowed to cool and poured slowly into ice water, 
which resulted in the isolation of 1,8-ditosyloxyanthrone as a chartreuse powder, yield 1.26g, 
 
78.8%, 1H NMR (CDCl3, 400MHz) δppm 2.37 (s, CH3, 6H), 4.31 (s, CH2, 1H), 7.22 (d, J = 8Hz, Ar- 
H, 2H), 7.26 (d, J = 8Hz, Ar-H, 4H), 7.55 (t, J = 8Hz, Ar-H, 2H), 7.79 (d, J = 8Hz, Ar-H, 4H), 7.88 (d, 
J  = 8Hz, Ar-H, 2H). IR (ATR) 2170, 2040, 2000, 1990 cm-1. MS-EI: 534.12 [M++. UV abs λmax  = 
221nm. 
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7.   Synthesis of emodin bianthrone (9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A mixture of compound (5) (0.03g, 0.117mmols), t-BuOK (0.0022g, 0.0198mmols) and DMF 
(0.02cm3) were irradiated in the microwave with stirring at 150W (t=130°C) for 30 minutes 
under sealed conditions. After cooling the mixture was then quenched with water, acidified to 
pH6 with 1M HCl and the resulting precipitate filtered using suction to give a pure product of 
emodin bianthrone as black crystals, yield 0.04g, 66.7%, 1H NMR (DMSO, 400MHz) δppm 2.73 
(s, CH3, 6H), 6.76 (s, Ar-H, 2H), 7.22 (s, Ar-H, 2H), 7.95 (s, Ar-H, 2H), 8.01 (s, Ar-H, 2H). IR (ATR) 
2170, 2050 cm-1. MS-EI: 509.46 [M++. UV abs λmax = 588nm. 
 
 
 
 
 
 
8.   Synthesis of 1,8,9,16-tetrahydroxybianthrone (10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A mixture of compound (6) (0.45g, 2mmols), t-BuOK(0.038g, 0.34mmols) and DMF (1cm3) were 
irradiated in the microwave with stirring at 150W (t=130°C) for 30 minutes under sealed 
conditions. After cooling the mixture was then quenched with water, acidified to pH 6 with 1M 
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HCl and the resulting precipitate filtered using suction to give a pure product of 1,8,9,16- 
tetrahydroxybianthrone as a saffron powder, yield 0.81g, 90.0%, 1H NMR (CDCl3, 400MHz) 
δppm 4.33 (s, CH2, 1H), 6.36 (d, J = 8Hz, Ar-H, 2H), 6.89 (dd, J = 8Hz, J = 1Hz, Ar-H, 1H), 6.89 
(dd, J = 8Hz, J = 1Hz, Ar-H, 2H), 7.38 (t, J = 8Hz, Ar-H, 2H), 7.68 (t, J = 8Hz, Ar-H, 2H), 7.82 (dd, J 
= 8Hz, J = 1Hz, Ar-H, 1H), 11.71 (s, OH, 2H), 12.06 (s, OH, 2H); there is a possibility of 
diasteriomeric mix present due to the H’s on the linking bond being either cis or trans in 
configuration hence there being more signals. IR (ATR) 2180, 2020, 2000, 1020, 1000 cm-1. MS- 
EI: 541.51 [M++. UV abs λmax = 260nm. 
 
 
 
 
 
9.   Synthesis of 1,9-dihydroxy-8,16-ditosyloxybianthrone (11) (NOVEL) 
 
 
 
 
 
 
 
A mixture of compound (7) (0.45g, 1.17mmols), t-BuOK (0.02g, 0.117mmols) and DMF (1cm3) 
were irradiated in the microwave with stirring at 150W (t=130°C) for 30 minutes under sealed 
conditions. After cooling the mixture was then quenched with water, acidified to pH 6 with 1M 
HCl and the resulting precipitate filtered using suction to give a pure product of 1,9-dihydroxy- 
8,16-ditosyloxybianthrone as a brown powder, yield 0.71g, 79.8%, 1H NMR (CDCl3, 400MHz) 
 
δppm 2.46 (s, CH3, 6H), 4.35 (s, CH, 1H), 7.16 (d, J = 8Hz, Ar-H, 4H), 7.55 (t, J = 8Hz, Ar-H, 4H), 
 
7.78 (d, J = 8Hz, Ar-H, 4H), 7.88 (d, J = 8Hz, Ar-H, 4H), 8.24 (dd, J = 8Hz, J = 1Hz, Ar-H, 4H), 12.40 
(s, OH, 2H). IR (ATR) 3120, 2180, 2040, 1990 cm-1. MS-EI: 758.41 [M++. UV abs λmax = 258nm. 
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10. Synthesis of 1,8,9,16-tetratosyloxybianthrone (12) (NOVEL) 
 
 
 
 
 
 
 
A mixture of compound (8) (0.79g, 2.0mmols), t-BuOK (0.038g, 0.34mmols) and DMF (1cm3) 
were irradiated in the microwave with stirring at 150W (t=130°C) for 30 minutes under sealed 
conditions. After cooling the mixture was then quenched with water, acidified to pH 6 with 1M 
HCl and the resulting precipitate filtered using suction to give a pure product of 1,8,9,16- 
tetratosyloxybianthrone as a red powder, yield 1.74g, 81.7%, 1H NMR (CDCl3, 400MHz) δppm 
2.42 (s, CH3, 9H), 7.33 (d, J = 8Hz, Ar-H, 8H), 7.67 (dd, J = 8Hz, J = 2Hz, Ar-H, 4H), 7.72 (t, J = 8Hz, 
 
Ar-H, 4H), 7.93 (d, J = 8Hz, Ar-H, 8H), 8.18 (dd, J = 8Hz, J = 2Hz, Ar-H, 4H) there are two lines of 
symmetry through the molecule hence there are only 6 signals. IR (ATR) 2160, 2050, 1990, 
1620, 1480, 1320 cm-1. MS-EI: 1075.61 [M++. UV abs λmax = 249nm. 
 
 
 
 
 
 
11. Synthesis of 1,8-dihydroxy-9,16-ditosyloxybianthrone (13) (NOVEL) 
 
 
 
 
 
 
 
A mixture of compound (6) (0.226g, 1.0mmols), compound (8) (0.549g, 1mmols), t-BuOK 
(0.038g, 0.34mmols) and DMF (1cm3) were irradiated in the microwave with stirring at 150W 
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(t=130°C) for 30 mins under sealed conditions. After cooling the mixture was then quenched 
with water, acidified to pH 6 with 1M HCl and the resulting precipitate filtered using suction to 
give the crude product.  This was then purified by silica column chromatography, elution with 
CHCl3  gave the pure product 1,8-dihydroxy-9,16-ditosyloxybianthrone, the third band (Rf  = 
0.48) as a dark red powder, yield 0.24g, 31.6%, 1H NMR (CDCl3, 400MHz) δppm 2.40 (s, CH3, 
 
6H), 7.27 (dd, J = 8Hz, J = 2Hz, Ar-H, 2H), 7.31 (d, J = 8Hz, Ar-H, 4H), 7.51 (dd, J = 8Hz, J = 1Hz, 
Ar-H, 2H), 7.63 (t, J = 8Hz, Ar-H, 2H), 7.75 (dd, J = 8Hz, J = 1Hz, Ar-H, 2H), 7.76 (t, J = 8Hz, Ar-H, 
2H), 7.80 (d, J = 8Hz, Ar-H, 4H), 8.28 (dd, J = 8Hz, J = 1Hz, Ar-H, 2H), 12.37 (s, OH, 2H). IR (ATR) 
 
3070, 1650, 1600, 1400, 1290, 1170, 980, 880, 750, 720, 680, 550 cm-1. MS-EI: 758.79 [M+]. UV 
 
abs λmax = 406nm. 
 
 
 
 
 
 
12. Synthesis of 1-[(2-aminoethyl)amino]-8-hydroxy anthraquinone (14) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A  mixture  of  compound  (4)  (5.48g,  0.01mols),  ethylenediamine  (2.4g,  0.04mols)  in  DCM 
(30cm3) was stirred under reflux for 2 hours. The solvent was removed under vacuum and the 
resulting crude product was purified twice using silica column chromatography, first as the 
second band (Rf = 0.61) eluted with DCM and second with CHCl3: methanol (MeOH) (5:1) giving 
a pure product of 1-[(2-aminoethyl)amino]-8-hydroxy anthraquinone as the second band (Rf = 
0.59) yielding black crystals, 0.97g, 34.4%, 1H NMR (CDCl3, 400MHz) δppm 2.42 (s, NH2, 2H), 
 
3.72 (t, J = 5Hz, CH2, 2H), 4.19 (t, J = 5Hz, CH2, 2H), 5.20 (s, NH, 1H), 6.92 (dd, J = 8Hz, J = 1Hz, 
Ar-H, 1H), 7.23 (dd, J = 8Hz, J = 1Hz, Ar-H, 1H), 7.40 (t, J = 8Hz, Ar-H, 1H), 7.43 (t, J = 8Hz, Ar-H, 
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1H), 7.66 (dd, J = 8Hz, J = 1Hz, Ar-H, 1H), 7.83 (dd, J = 8Hz, J = 1Hz, Ar-H, 1H). IR (ATR) 3290, 
 
3040, 2850, 2170, 1610, 1300, 1200, 1180, 740 cm-1. MS-EI: 282 [M++. UV abs λmax = 525nm. 
 
 
 
 
 
13. Synthesis of 1-[(3-aminopropyl)amino]-8-hydroxyanthraquinone (15) and 1-[(3- 
aminopropyl)amino]-8-tosyloxyanthraquinone (16) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 16 
 
 
 
 
 
 
A mixture of compound (4) (5.48g, 0.01mols) and 1,3-diaminopropane (2.97g, 0.04mols) in 
DCM (30cm3) were stirred under reflux for 2 hours. The solvent was removed under vacuum 
and the resulting crude product was purified twice using silica column chromatography, first as 
the second band (Rf = 0.78) eluted with DCM and second with CHCl3: MeOH (5:1) to give two 
products:   1-[(3-aminopropyl)amino]-8-hydroxyanthraquinone the first band (Rf    = 0.67) as a 
dark purple powder, yield 1.18g, 9.96%, 1H NMR (CDCl3, 400MHz) δppm 1.88 (quin, J = 6Hz, 
CH2, 2H), 2.37 (s, CH3, 3H), 2.91 (t, J = 6Hz, CH2, 2H), 3.37 (quart, J = 6Hz, CH2, 2H), 7.00 (dd, J = 
8Hz, J = 1Hz, Ar-H, 1H), 7.20 (dd, J = 8Hz, J = 1Hz, Ar-H, 1H), 7.47 (t, J = 8Hz, Ar-H, 1H), 7.52 (dd, 
J = 8Hz, J = 1Hz, Ar-H, 1H), 7.54 (t, J = 8Hz, Ar-H, 1H), 9.38 (s, OH, 1H). IR (ATR) 3300, 2960, 
2870, 1630, 1590, 1520, 1480, 1280, 1210, 1170, 1070, 820, 730 cm-1. MS-EI: 296 [M+]. UV abs 
 
λmax  = 512nm and 1-[(3-aminopropyl)amino]-8-tosyloxyanthraquinone the second band (Rf   = 
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0.54) as a dark red powder, yield 1.35g, 7.49%, 1H NMR (CDCl3, 400MHz) δppm 1.94 (quin, J = 
 
7Hz, CH2, 2H), 2.96 (t, J = 7Hz, CH2, 2H), 3.43 (quar, J = 7Hz, CH2, 2H), 7.07 (dd, J = 6Hz, J = 3Hz, 
Ar-H, 1H), 7.26 (d, J = 8Hz, Ar-H, 2H), 7.36 (dd, J = 8Hz, J = 1Hz, Ar-H, 1H), 7.49 (t, J = 8Hz, Ar-H, 
1H), 7.49 (d, J = 8Hz, Ar-H, 1H), 7.61 (t, J = 8Hz, Ar-H, 1H), 7.77 (d, J = 8Hz, Ar-H, 2H), 8.22 (dd, J 
 
= 8Hz, J = 1Hz, Ar-H, 1H), 9.57 (s, NH, 1H). IR (ATR) 2980, 2910, 1670, 1600, 1510, 1310, 1220, 
 
1180, 850, 740, 670, 550 cm-1. MS-EI: 450.97 [M+]. UV abs λmax = 521nm. 
 
 
 
 
14. Synthesis of 1-[(4-aminobutyl)amino]-8-hydroxyanthraquinone (17) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A mixture of compound (4) (5.48g, 0.01mols) and putrescine (3.53g, 0.04mols) in DCM (30cm3) 
were  stirred  under  reflux  for  2  hours.  The  solvent  was  removed  under  vacuum  and  the 
resulting crude product was purified twice using silica column chromatography, first as the 
second band (Rf    = 0.71) eluted with DCM and second as the second band (Rf    = 0.63) with 
CHCl3: MeOH (5:1) to give 1-[(4-aminobutyl)amino]-8-hydroxyanthraquinone as a dark purple 
powder, yield 1.29g, 10.39%, 1H NMR (CDCl3, 400MHz) δppm 1.69 (quin, J = 7Hz, CH2, 2H), 1.77 
(quin, J = 7Hz, CH2, 2H), 2.24 (s, NH, 1H), 2.86 (t, J = 7Hz, CH2, 2H), 3.27 (quar, J = 7Hz, CH2, 2H), 
6.96 (d, J = 6Hz, Ar-H, 1H), 6.97 (d, J = 6Hz, Ar-H, 1H), 7.24 (t, J = 8Hz, Ar-H, 1H), 7.29 (d, J = 8Hz, 
Ar-H, 1H), 7.57 (t, J = 8Hz, Ar-H, 1H), 8.17 (d, J = 8Hz, Ar-H, 1H), 9.50 (s, OH, 1H). IR (ATR) 3050, 
2970, 2850, 2160, 1590, 1300, 1180, 870, 750, 550 cm-1. MS-EI: 310.95 [M++.  UV abs λmax  = 
 
527nm. 
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4.2 Yeast Growth Inhibition Assay 
 
 
The growth inhibitory activity of the compounds was determined by screening S. pombe, L. 
starkeyi and S. cerevisiae using the following method. 
 
Yeast species were inoculated into relevant media; S. pombe (NJ2 h-  ura4-D18 leu1-32 ade6- 
M210 his7-366)112  into yeast extract broth (YE)113, L. starkeyi (strain NCYC2710)1  and S. 
cerevisiae (strain BY4741a, a derivative of S288C Genotype is MATahis3   1 leu2   0 met15 
0ura3   0)114 into complex media (YPD).115 The culture was then incubated for 12 hours at 30°C 
with shaking at 200 rpm. Stock solutions of the compounds were prepared in 20% DMSO and 
culture media. DMSO and culture media were all used as controls for the experiment. 3 x 104 
yeast cells were transferred into the wells of a 96- well plate. A 1 in 2 serial dilution of the 
compounds was then performed starting at the stock concentration indicated in the Table. The 
well plates were finally inspected visually for growth of yeast after 24 hours of incubation at 
30°C. Growth was indicated by full or partial white appearance of yeast on the bottom of the 
 
wells. The MIC of the compounds was determined to be the well before yeast growth was first 
seen. The experiment was repeated three times to ensure reproducibility of the results. 
 
To determine whether compounds had antifungal activity, cells were taken from the well on 
the micro-titre plate at the concentration where lack of yeast growth was first observed. These 
cells were inoculated into fresh culture media, to remove presence of compound and grown 
for 24hours at 30oC with shaking at 200rpm. Compounds were determined to be fungicidal, if 
no growth was observed and fungistatic, if normal growth was seen. 
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S. pombe L. starkeyi S. cerevisiae 
Compound MW mmol µmol   log(µmol) S or C mmol µmol   log(µmol) S or C mmol µmol   log(µmol) S or C 
Emodin (1) 
 
1,8-dihydroxyanthraquinone (2) 
1-hydroxy-8- 
tosyloxyanthraquinone (3) 
 
1,8-ditosyloxyanthraquinone (4) 
emodin anthrone (5) 
1,8-dihydroxyanthrone (6) 
 
1-hydroxy-8-tosyloxyanthrone (7) 
1,8-ditosyloxyanthrone (8) 
emodin bianthrone (9) 
1,8,9,16-tetrahydroxybianthrone 
(10) 
1,9-dihydroxy-8,16- 
ditosyloxybianthrone (11) 
1,8,9,16-tetratosyloxybianthrone 
(12) 
1,8-dihydroxy-9,16- 
ditosyloxybianthrone (13) 
1-[(2-aminoethyl)amino]-8- 
hydroxyanthraquinone (14) 
1-[(3-aminopropyl)amino]-8- 
hydroxyanthraquinone (15) 
1-[(3-aminopropyl)amino]-8- 
tosyloxyanthraquinone (16) 
1-[(4-aminobutyl)amino]-8- 
hydroxyanthraquinone (17) 
Hypericin (18) 
270.24 
 
239.22 
 
394.40 
 
548.58 
256.25 
226.23 
 
380.41 
534.60 
510.49 
 
450.44 
 
758.81 
 
1065.17 
 
758.81 
 
282.29 
 
296.32 
 
450.51 
 
310.35 
504.44 
1.2950   1295.0   3.1123 s 
 
1.4600   1460.0   3.1644 s 
 
1.7700   1770.0   3.2480 s 
 
1.2800   1280.0   3.1072 s 
0.0976 97.6   1.9894 s 
0.0553 55.3   1.7427 s 
 
0.0657 65.7   1.8176 s 
0.0468 46.8   1.6702 s 
0.9800 980.0   2.9912 s 
 
0.1400 140.0   2.1461 s 
 
0.4600 460.0   2.6628 s 
 
a a a a 
 
0.4600 460.0   2.6628 c 
 
0.4400 440.0   2.6435 s 
 
0.4200 420.0   2.6232 c 
 
0.1400 140.0   2.1461 s 
 
0.2000 200.0   2.3010 c 
1.9800   1980.0   3.2967 c 
2.590      2590     3.413    s 
2.910      2910     3.464    s 
a a             a           a 
a a             a           a 
39.000 39000 4.591 c 
22.100 22100 4.344 s 
 
0.657        657      2.818    s 
0.468        468      2.670    s 
0.979        979      2.991    s 
 
0.555        555      2.744    s 
 
0.922        922      2.965    s 
 
a             a             a           a 
 
0.922        922      2.965    s 
 
0.886        886      2.947    s 
 
0.844        844      2.926    s 
 
0.555        555      2.744    c 
 
0.403        403      2.605    s 
0.991        991      2.996    s 
1.300 1300 3.114 s 
 
2.910 2910 3.464 s 
 
1.770 1770 3.248 s 
 
0.638 638 2.805 s 
1.950 1950 3.290 c 
0.553 553 2.743 s 
 
0.329 329 2.517 s 
0.234 234 2.369 s 
0.979 979 2.991 s 
 
0.555 555 2.744 s 
 
0.461 461 2.664 s 
 
a a a a 
 
0.922 922 2.965 s 
 
0.886 886 2.947 s 
 
0.844 844 2.926 s 
 
0.555 555 2.744 c 
 
0.201 201 2.303 s 
0.991 991 2.996 s 
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Plate pictures for the growth inhibition of S. pombe. 
 
 
 
 
 
Control 
 
Control+ DMSO 
 
 
Compound 1 
Concentration (mM) 
 
Compound 2 
 
ConccntrJtion (mM) 
 
Compound 3 
 
Conccntr.:Jtion (mM) 
 
Compound4 
 
Concentration (mM) 
 
Compound 5 
Concentration (rnM) 
 
Compound 6 
Concentrt1on (mM) 
 
Compound 7 
Concentration (mM) 
 
Compound 8 
 
ConcentratiOn (mM) 
 
Compound 9 
Concentration (rnM) 
 
Compound 10 
 
Concentration (rnM) 
 
Compound 11 
 
ConccntrJtion (mM) 
 
Compound 12 
 
Conc entration (mM) 
 
Compound 13 
 
Concemmtion (mM) 
 
Compound 14 
 
Concentration (rnM) 
 
Compound 15 
 
 
1. 2H 0.64 0.32 0.16  O.OH 0.04 1.2H  0.64 0.32      0.16 O.OH       0.04 
 
3.90 1.95 0.98     0.49 0.24  0.12  3.90  1.95 0.98 0.49 0.24    0.12 
 
 
 
1.96    O.!J8 0.4!J 0.24 0.12 0.05 1.96 0.98 0.49 0.24    0.12 0.06 
 
2.22      1.11   0.56 0.28 0.14 0.07 2.22  1.11 0.56    0.28 0.14    0.07 
 
 
 
 
 
 
 
 
0.92 0.46 0.23 0.12 0.06 0.03  0.92 0.4G 0.23    0.12 0.06    0.03 
 
Concentration (mM) 
 
Compound 16 
 
ConcentratiOn (mM) 
 
Compound 17 
 
 
 
_A! 
2.22  1.11   0.55 0.2H 0.14 0 07 
 
- . R' \ 
-· -)J 
2.22  1.11    0.55 0.2H      0.14  0.07 
 
Concentration (mM) 
 
Compound 18 
 
Conccntrw tion (mM) 
 
3.22      Uil C Ull D 40  0.20 0.10 3.22  1.61    O.H1      0.40    0.20      0.10 
 
1.98     0.99 0.50 0.25  0.12 0.06  1.98     0.99 0.50    0.25  0.12     0.06 
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Plate pictures for the growth inhibition of L starkeyi 
 
 
 
 
 
Control 
 
Control+ DMSO 
 
Compound 1 
Concentr"tion (mlvl) 
 
Compound 2 
 
ConccntrJtion (mlvl) 
 
Compound  3 
 
Concentration (mM} 
 
Compound 4 
 
Concentration (mM} 
 
Compotmd 5 
 
ConccntrJtion (mM} 
 
Compound 6 
ConccntrJtion (mf\11) 
 
Compound 7 
Concentriltion (mM) 
 
Compound 8 
Concentrat on (mM} 
 
 
2.93  1.46       0.73    0.36 0.18  0.09 2.93  1.46 0.73  0.36  0.18    0.09 
 
 
 
 
 
1.28       0.64 0.32  0.16  0.08  0.04 1.2!! o.64 o.32    o.l6 o.oa    o.o4 
 
3.90  1.95     0.98    0.49  0.24 0.12 3.90  1.95 0.98  0.49 0.24    0.12 
 
Compound 9 
Concentrot1on (mf\11) 
 
Compound 10 
 
Concentrot ion (mM) 
 
Compound 11 
 
Concentrotion (mM) 
 
Compound 12 
 
Concntration (mM) 
 
Compound 13 
 
Concentrot1on (mM) 
 
Compound 14 
 
Concentrot1on (mM) 
 
Compound 15 
 
Concntr"tion (mM} 
 
Compound 16 
 
Conn•ntra tion (rnM) 
 
Compound 17 
 
1.96    0.98 0.49    0.24 
 
0.12 0.06 
 
1.96 0.98  0.49  0.24      0.12 0.06 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.22     0.11 
 
_. '  - 1) 
 
Concentration (mM) 
 
Compound 18 
 
3.22      1.61   0.!!1     0.40 0.20 0.10 
 
Concentration (mM) 
 
1.98    0.99  0.50 0.25 0.12  0.06 
 
1.98 0.99 
 
0.50     0.25 0.12     0.06 
-  60  -  
 
 
 
 
 
 
Plate pictures for the growth inhibition of S. cerevisiae 
 
 
 
 
 
 
Control 
 
Control+ DMSO 
 
Compound 1 
Concentration (mM) 
 
Compound 2 
 
Concentration (mM) 
 
Compound 3 
Concentration (mM) 
 
Compound 4 
Concentration (mM) 
 
Compound 5 
Concentration (mM) 
 
Compound 6 
Concentration (mM) 
 
Compound 7 
Concentratoi n (mM) 
 
Compound 8 
Concentration (mM) 
 
Compound 9 
Concentration (mM) 
 
Compound 10 
Concentration (mM) 
Compound 11 
Concentration (mM) 
 
Compound 12 
 
Concentration (mM) 
Compound 13 
Concentration (mM) 
 
Compound 14 
Concentration (mM) 
Compound 15 
Concentration (mM) 
 
Compound 16 
 
Concentration (mM) 
Compound 17 
Concentration (mM) 
 
Compound 18 
 
Concentration (mM) 
 
1.77     0.89  0.44  0.22  0.11    0.06  1.77  0.89  0.44  0.22  0.11      0.06 
 
 
1.28      0.64  0.32  0.16  0.08  0.04  1.28  0.64  0.32      0.16  0.08      0.04 
 
3.90 1.95       0.98      0.49  0.24  0.12  3.90  1.95 0.98 0.49  0.24     0.12 
1 '"'!"  \_.; ·-   lt .L_"").  .. (")'"-0 L   • - . •. . .J'  . . ... -  .  !' \ .. \.  . 
 
2.22 1.11   0.55  0.28 0.14 0.07  2.22  1.11 0.55  0.28 0.14  0.07 
 
3.22      1.61 0.81    0.40      0.20  0.10  3.22  1.61   0.81  0.40  0.20      0.10 
;I  
1.98     0.99  0.50       0.25 0.12  0.06  1.98      0.99  0.50     0.25 0.12     0.06 
-  61  -  
 
 
 
 
 
 
Repeat of compounds (5), (6), (7) and (8) at lower concentrations in 5. pombe. 
 
 
 
 
 
 
 
Control 
 
Control+ DMSO 
 
Compound 5 
Concentratoi n (mM) 
 
Compound 6 
 
Concentration (mM) 
 
Compound 7 
 
Concentration (mM) 
 
Compound 8 
 
Concentrat on (mM) 
 
0.88     0.44  0.22  0.11      0.06  0.03  0.88  0.44      0.22  0.11  0.06     0.03 
 
 
0.53     0.26  0.13  0.07      0.03  0.02  0.53  0. 26 0.13  0.07  0.03     0.02 
 
0.37    0.19  0.09    0.05  0.02 0.01  0.37  0.19  0.09  0.05  0.02  0.01 
